Therapeutic Effect of Vitamin D3 in Multiple Sclerosis Patients.
Immunol Invest. 2011 May 4.
Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P.
Molecular and Medicine Research Center, Department of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, I.R. Iran.
Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the central nervous system are damaged. The damage leads to demyelination and scarring as well as a broad spectrum of signs and symptoms. The epidemiological data suggest a possible influence of vitamin D as an immunomodulatory agent on multiple sclerosis susceptibility as well as on clinical course of the disease. We investigated the effects of short-term vitamin D3 therapy on Iranian patients with MS.
In a prospective randomized controlled trial study, 62 MS patients received 300,000 IU/month vitamin D3 or placebo as intramuscular injection for 6 months.
Our results showed no significant difference between the treatment and the control groups in the expanded disability status scale scores and number of gadolinium-enhancing lesions during the 6-month treatment period.
After 6 months, the levels of cell proliferation in the vitamin D treatment group were significantly lower than the control group.
Also, the levels of transforming growth factor-beta and interleukin-10 in the vitamin D treatment group were significantly higher than the control group.
This result suggests that vitamin D therapy may help prevent the development of MS and could be a useful addition to the therapy.
300,000 IU monthly is about 10,000 IU daily
This was injection, not oral
No difference during the first 6 months – when the vitamin D levels were still rising.
Would have been nice if the study had started with a bigger dose and/or had lasted longer.
See also VitaminDWiki
- Overview MS and Vitamin D - includes the following item
- All items in category MS and Vitamin D 201 items
- Yet again - more than 10,000 IU of vitamin D treats MS – July 2011
- 20,000 IU vitamin D and MS – less fatigue and relapse Dec 2010